See more : BOA Acquisition Corp. (BOAS-UN) Income Statement Analysis – Financial Results
Complete financial analysis of Futura Medical plc (FAMDF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Futura Medical plc, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Premium Nickel Resources Ltd. (PNRL.V) Income Statement Analysis – Financial Results
- International Tower Hill Mines Ltd. (1I1.F) Income Statement Analysis – Financial Results
- Roboserver Systems Corp. (RBSY) Income Statement Analysis – Financial Results
- Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München (MURGY) Income Statement Analysis – Financial Results
- Media Technologies Inc. (MDTC) Income Statement Analysis – Financial Results
Futura Medical plc (FAMDF)
About Futura Medical plc
Futura Medical plc, a pharmaceutical company, develops pharmaceutical and healthcare products for the consumer healthcare markets focusing on sexual health and pain relief management. Its lead product is MED3000, a topical gel for the treatment of erectile dysfunction. The company also develops pain relief products, including TPR100, a topical diclofenac pain relief gel; CBD100, a topical cannabidiol formulation; and TIB200, a topical ibuprofen pain relief gel. The company was incorporated in 2001 and is headquartered in Guildford, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.10M | 0.00 | 0.00 | 0.00 | 31.78K | 0.00 | 362.73K | 170.36K | 29.48K | 43.93K | 370.90K | 75.00K | 158.00K | 125.00K | 50.00K | 150.00K | 15.00K | 0.00 | 2.00K | 130.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.33M | 24.73K | 19.81K | 25.01K | 0.00 | 19.85K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.77M | -24.73K | -19.81K | -25.01K | 31.78K | -19.85K | 362.73K | 170.36K | 29.48K | 43.93K | 370.90K | 75.00K | 158.00K | 125.00K | 50.00K | 150.00K | 15.00K | 0.00 | 2.00K | 130.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 57.22% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.05M | 4.13M | 3.77M | 1.93M | 10.05M | 6.04M | 4.10M | 3.51M | 4.78M | 2.37M | 1.98M | 1.44M | 1.00K | 762.00K | 810.00K | 1.40M | 1.52M | 1.08M | 1.55M | 960.00K | 627.00K | 811.00K | 683.00K | 207.00K |
| General & Administrative | 6.69M | 2.74M | 2.09M | 1.00M | 1.14M | 1.23M | 1.12M | 1.21M | 1.37M | 1.21M | 926.12K | 1.10M | 2.19M | 632.00K | 721.00K | 910.00K | 1.12M | 935.00K | 721.00K | 711.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.69M | 2.74M | 2.09M | 1.00M | 1.14M | 1.23M | 1.12M | 1.21M | 1.37M | 1.21M | 926.12K | 1.10M | 2.19M | 632.00K | 721.00K | 910.00K | 1.12M | 935.00K | 721.00K | 711.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -4.82K | -4.07K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -47.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.74M | 6.87M | 5.87M | 2.93M | 11.20M | 7.27M | 5.22M | 4.72M | 6.15M | 3.57M | 2.90M | 2.53M | 2.26M | 1.46M | 1.58M | 2.32M | 2.63M | 2.11M | 2.36M | 1.70M | 1.51M | 1.30M | 1.34M | 392.00K |
| Cost & Expenses | 10.06M | 6.87M | 5.87M | 2.93M | 11.20M | 7.27M | 5.22M | 4.72M | 6.15M | 3.57M | 2.90M | 2.53M | 2.26M | 1.46M | 1.58M | 2.32M | 2.63M | 2.11M | 2.36M | 1.70M | 1.51M | 1.30M | 1.34M | 392.00K |
| Interest Income | 71.80K | 0.00 | 0.00 | 924.00 | 22.28K | 27.58K | 19.32K | 14.71K | 38.33K | 48.26K | 9.53K | 18.49K | 24.00K | 19.00K | 14.00K | 97.00K | 161.00K | 136.00K | 133.00K | 177.00K | 48.00K | 60.00K | 22.00K | 6.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00K | 1.00K | 29.00K | 16.00K |
| Depreciation & Amortization | 130.27K | 24.73K | 19.81K | 25.01K | 20.70K | 19.85K | 13.43K | 6.25K | 6.96K | 4.53K | 3.78K | 2.18K | 4.00K | 8.00K | 11.00K | 16.00K | 15.00K | 11.00K | 13.00K | 16.00K | 13.00K | 14.00K | 9.00K | 1.00K |
| EBITDA | -6.83M | -6.85M | -5.85M | -2.90M | -11.14M | -7.25M | -4.84M | -4.55M | -6.11M | -3.52M | -2.53M | -2.45M | -2.09M | -1.33M | -1.52M | -2.16M | -2.61M | -1.96M | -2.34M | -1.57M | -1.45M | -1.22M | -1.31M | -385.00K |
| EBITDA Ratio | -220.37% | 0.00% | 0.00% | 0.00% | -35,065.34% | 0.00% | -1,335.03% | -2,669.51% | -20,728.20% | -8,018.17% | -681.52% | -3,271.66% | -1,310.76% | -1,047.20% | -3,002.00% | -1,374.67% | -16,320.00% | 0.00% | -110,500.00% | -1,060.77% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -6.96M | -6.87M | -5.87M | -2.93M | -11.16M | -7.27M | -4.86M | -4.55M | -6.12M | -3.53M | -2.53M | -2.46M | -2.10M | -1.34M | -1.53M | -2.18M | -2.62M | -2.11M | -2.36M | -1.58M | -1.51M | -1.30M | -1.34M | -392.00K |
| Operating Income Ratio | -224.57% | 0.00% | 0.00% | 0.00% | -35,130.49% | 0.00% | -1,338.73% | -2,673.17% | -20,751.81% | -8,028.47% | -682.54% | -3,274.57% | -1,328.48% | -1,068.80% | -3,052.00% | -1,450.00% | -17,493.33% | 0.00% | -117,800.00% | -1,212.31% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 71.80K | 0.00 | 0.00 | 924.00 | 22.28K | 27.58K | 19.32K | 14.71K | 38.33K | 48.26K | 9.53K | 18.49K | 24.21K | 19.00K | 14.00K | 97.00K | 161.00K | 136.00K | 134.00K | 177.00K | 47.00K | 59.00K | -7.00K | -10.00K |
| Income Before Tax | -6.89M | -6.87M | -5.87M | -2.93M | -11.14M | -7.24M | -4.84M | -4.54M | -6.08M | -3.48M | -2.52M | -2.44M | -2.08M | -1.32M | -1.51M | -2.08M | -2.46M | -1.97M | -2.22M | -1.40M | -1.46M | -1.24M | -1.35M | -402.00K |
| Income Before Tax Ratio | -222.25% | 0.00% | 0.00% | 0.00% | -35,060.37% | 0.00% | -1,333.41% | -2,664.54% | -20,621.79% | -7,918.62% | -679.97% | -3,249.92% | -1,313.29% | -1,053.60% | -3,024.00% | -1,385.33% | -16,420.00% | 0.00% | -111,150.00% | -1,076.15% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -379.07K | -1.02M | -908.60K | -519.09K | -2.22M | -1.36M | -936.34K | -842.25K | -997.04K | -480.69K | -313.68K | -260.79K | -260.00K | -226.00K | -119.00K | -143.00K | -209.00K | -196.00K | -287.00K | -170.00K | -101.00K | -152.00K | -100.00K | -30.00K |
| Net Income | -6.51M | -5.85M | -4.96M | -2.41M | -8.92M | -5.88M | -3.90M | -3.70M | -5.08M | -3.00M | -2.21M | -2.18M | -1.82M | -1.09M | -1.39M | -1.94M | -2.25M | -1.78M | -1.94M | -1.23M | -1.36M | -1.09M | -1.25M | -372.00K |
| Net Income Ratio | -210.03% | 0.00% | 0.00% | 0.00% | -28,067.50% | 0.00% | -1,075.27% | -2,170.15% | -17,239.25% | -6,824.38% | -595.40% | -2,902.20% | -1,148.73% | -872.80% | -2,786.00% | -1,290.00% | -15,026.67% | 0.00% | -96,800.00% | -945.38% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.02 | -0.02 | -0.02 | -0.01 | -0.04 | -0.04 | -0.03 | -0.04 | -0.05 | -0.03 | -0.03 | -0.03 | -0.03 | -0.02 | -0.02 | -0.03 | -0.04 | -0.03 | -0.04 | -0.03 | -0.03 | -0.03 | -0.04 | -0.01 |
| EPS Diluted | -0.02 | -0.02 | -0.02 | -0.01 | -0.04 | -0.04 | -0.03 | -0.04 | -0.05 | -0.03 | -0.03 | -0.03 | -0.03 | -0.02 | -0.02 | -0.03 | -0.04 | -0.03 | -0.04 | -0.03 | -0.03 | -0.03 | -0.04 | -0.01 |
| Weighted Avg Shares Out | 294.91M | 287.48M | 271.05M | 243.72M | 204.66M | 131.94M | 121.32M | 101.93M | 99.59M | 89.96M | 78.04M | 75.17M | 72.18M | 67.95M | 62.58M | 57.95M | 55.92M | 52.60M | 48.96M | 48.34M | 43.15M | 40.96M | 30.88M | 27.36M |
| Weighted Avg Shares Out (Dil) | 294.91M | 287.48M | 271.05M | 243.72M | 204.66M | 131.94M | 121.32M | 101.93M | 99.59M | 89.96M | 78.04M | 75.17M | 72.18M | 67.95M | 62.58M | 57.95M | 55.92M | 52.60M | 48.96M | 48.34M | 45.29M | 40.96M | 30.88M | 27.36M |
Futura Medical shares jump 22% in the wake of FDA green light
Shares in Futura Medical PLC (AIM:FUM, OTC:FAMDF) jumped by 22% in the first half-hour of trading following the news that its topical erectile dysfunction (ED) gel, MED3000, received over-the-counter (OTC) marketing approval from the US Food and Drug Administration (FDA)....
Futura Medial achieves 'huge milestone' with US sign-off
In a significant milestone for UK-based Futura Medical PLC (AIM:FUM, OTC:FAMDF) and a first for the US, the Food and Drug Administration (FDA) has approved the over-the-counter marketing of the company's innovative topical gel for erectile dysfunction (ED). MED3000 can now...
Futura Medical's James Barder on what next for Eroxon after UK launch
Here Futura Medical PLC (AIM:FUM, OTC:FAMDF) CEO James Barder discusses the UK launch of Eroxon, the company's over-the-counter erectile dysfunction treatment, with Thomas Warner of Proactive. Eroxon is now available at Boots stores and online.
Futura Medical hails UK launch of ED drug as major milestone
Futura Medical PLC (AIM:FUM, OTC:FAMDF) has announced the UK launch of its groundbreaking erectile dysfunction (ED) treatment gel, Eroxon, hailing the event as a 'significant milestone'. Futura's transdermal drug delivery technology has been used to develop a fast-acting topical gel with minimal...
Futura Medical primed for key year, says broker
Futura Medical PLC (AIM:FUM, OTC:FAMDF)'s prelims were ‘broadly in with expectations', according to corporate broker Liberum, which repeated its ‘buy' recommendation and 121p a share price target for the stock. The results were notable in so much as they form...
Futura Medical gears up for ED gel launch as it eyes US approval
Futura Medical PLC (AIM:FUM, OTC:FAMDF) said it ‘firmly focused' on gaining marketing approval for its erectile dysfunction (ED) product in the US, with a decision from the drug regulator expected at some point next quarter. The green light from the Food...
Futura Medical moves closer to US approval for innovative erectile dysfunction treatment
Futura Medical PLC (AIM:FUM, OTC:FAMDF) has confirmed the submission of a comprehensive response to the US Food and Drug Administration (FDA) regarding its innovative topical gel treatment for erectile dysfunction (ED), known as MED3000. It has now provided all requested...
Futura Medical says commercial launch of breakthrough ED gel set for the first half of this year
Futura Medical PLC (AIM:FUM, OTC:FAMDF) has announced that its partner, Cooper Consumer Health, has begun pre-launch activities for the launch of MED3000. Also known as Eroxon, MED3000 is a breakthrough, topical gel formulation for the treatment of erectile dysfunction (ED).
Futura Medical hails progress of MED3000 gel
Futura Medical PLC (AIM:FUM, OTC:FAMDF) hailed the regulatory and marketing progress of its erectile dysfunction gel, MED3000, over the past year, which has gained marketing authorisation in three Middle Eastern countries and is being reviewed by the US regulator. The...
Futura Medical erectile dysfunction gel in a strong position for FDA approval, says broker
Futura Medical PLC (AIM:FUM, OTC:FAMDF)'s MED3000 erectile dysfunction gel is in a ‘strong position' to be approved by the US Food & Drug Administration. That's according to the company's broker Liberum, which reckons the shares are worth 121p each –...
Source: https://incomestatements.info
Category: Stock Reports